Our team of PhD-level experts has extensive experience working with complex conjugated platforms such as ADCs and multispecific therapeutics throughout all stages of development.
Through strategic application of advanced LC-MS and biophysical-based analytics and data analysis, BioAnalytix develops and applies analytic methods to accurately quantify and characterize critical ADC and bispecific/multispecific conjugation structures, stoichiometries, and binding site ratios.
Our top 12 analytic programs include:
Antibody Drug Conjugate:
Advance. De-Risk. Accelerate.
From identifying and characterizing the specific molecular attributes of your platform’s conjugation sites in candidate development, to quantifying and characterizing CQAs and PTM progression in pivotal clinical trials in vivo, we will be happy to work with you, bringing our insights, experience, and method development expertise to accelerate your ADC and multispecific therapeutics programs. Contact our experts today »